inōtiv
analyze. answer. advance.

Target Sufficiency® enables key decisions in antibody-drug conjugate (ADC) therapeutics

Imagine a protein assay equivalent to rtPCR—sensitive, precise, highly specific, and for any protein. Our Target Sufficiency platform employs high resolution mass spectrometry (MS) to simultaneously quantify multiple proteins in diverse specimen types, including cells, tissues, biofluids and archival FFPE sections.

CURRENT ADC TARGETS ASSAYS AVAILABLE

HER2, EGFR, EpCAM, TROP2, LIV1, ROR1, CEACAM5, MSLN, BCMA, CD19

We can produce a new assay for *any* protein.

WHAT TARGET PROTEIN EXPRESSION LEVEL IS REQUIRED FOR EFFICACY?

HER2-targeted ADC produce clinical responses in tumors expressing lower HER2 protein levels than are required for traztuzimab and other HER2 antibody blocking drugs. To establish the relationship between ADC target expression and efficacy requires an assay platform that can precisely measure the target across a broad abundance range. Quantitation with our Target Sufficiency® platform measures ADC targets HER2 and TROP2 over a 100-fold (HER2 in NSCLC) and 15-fold (HER2 and TROP2 in HNSCC) expression range in solid tumors (left). Target Sufficiency® provides linear quantitation over a 200-fold expression range in tissues (right).

Target Sufficiency answers key questions:

Does this tumor type express the ADC target protein and at what quantitative abundance?

Which preclinical models express the ADC target in quantitatively similar levels?

Can differences in ADC target expression explain efficacy in my clinical trial?





Target Sufficiency® can quantify ADC targets in tumor tissues. Levels of ADC targets may dictate efficacy of ADC therapeutics. Retrospective analysis in tissue specimens can inform interpretation of trial outcomes.

800.793.7287 | RMSinfo@inotivco.com

inotivco.com